Olaratumab + Doxorubicin for Metastatic Soft-Tissue Sarcoma
1 Vues
• 07/18/23
0
0
Intégrer
administrator
Les abonnés
William D. Tap, MD; Richard F. Riedel, MD; Victor M. Villalobos, MD, PhD; and Kristen N. Ganjoo, MD, comment on the overall survival benefit seen in the phase II study of doxorubicin and olaratumab, the phase III ANNOUNCE trial, and patient selection for this regimen and data for other regimens.
Montre plus
Commentaires de Facebook
SORT BY-
Meilleures Commentaires
-
Derniers Commentaires